Karakterizacija sojeva Streptococcus pneumoniae izolovanih od pacijenata sa meningitisom pre uvođenja pneumokokne konjugovane vakcine u Srbiji

Sara D. Milojević; Dušan Kekić; Ina Gajić; Vera Mijač; Nataša Opavski

doi:10.5937/mp71-22252

Sara D. Milojević Univerzitet u Beogradu, Medicinski fakultet
Dušan Kekić Institut za mikrobiologiju i imunologiju, Medicinski fakultet Beograd
Ina Gajić Institut za mikrobiologiju i imunologiju, Medicinski fakultet Beograd
Vera Mijač Institut za mikrobiologiju i imunologiju, Medicinski fakultet Beograd
Nataša Opavski Institut za mikrobiologiju i imunologiju, Medicinski fakultet Beograd

DOI: https://doi.org/10.5937/mp71-22252

Abstract

Bakterijski meningitis je teško oboljenje koje je najčešće izazvano pneumokokom i javlja se obično kod dece ≤ 2 godine, kao i osoba ≥ 65 godina. Iskustvo iz zemalja koje su uvele pneumokoknu konjugovanu vakcinu (PCV) je pokazalo da je došlo do značajnog pada incidencije pneumokoknog meningitisa, izmene distribucije serotipova i smanjenja rezistencije na antibiotike. U Srbiji je u aprilu 2018. uvedena obavezna imunizacija dece PCV. Kako bi se mogao pratiti efekat PCV neophodno je imati podatke o sojevima u prevakcinalnoj eri. Ovaj rad ispituje distribuciju serotipova, pokrivenost cirkulišućih serotipova PCV, kao i osetljivost na antibiotike pneumokoka izolovanih od pacijenata sa meningitisom u prevakcinalnom periodu Srbije. Rezultati ovog rada predstavljaju polaznu osnovu za praćenje efekata PCV u Srbiji.

References

(1) Murray P, Rosenthal K, Pfaller M. Medical Microbiology: Streptococcus and Enterococcus. ed. 8. Philadelphia: Elsevier; 2016.

(2) European Centre for Disease Prevention and Control. Invasive pneumococcal disease. In: ECDC. Annual epidemiological report for 2016. Stockholm: ECDC; 2018. dostupno na sajtu: https://ecdc.europa.eu/en/publications-data/invasive-pneumococcal-disease-annual-epidemiological-report-2016

(3) Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev. 2010 Jul; 23(3): 467-492.

(4) Dimitrijević D, Drakulović M, Milinković M, Plavša D, Simić D, Stošić M. et al. Izveštaj o zaraznim bolestima u Republici Srbiji za 2017. godinu: Bakterijski meningitisi (Meningitis bacterialis). Beograd: Institut za javno zdravlje Srbije „Milan Jovanović Batut“; 2018.

(5) Geno KA, Gilbert GL, Song JY, Skovsted, IC, Klugman KP, Jones C. et al. Pneumococcal capsules and their types: past, present and future. Clin Microbiol Rev. 2015 Jun; 28(3): 871-899.

(6) Cherazard R, Epstein M, Doan TL, Salim T, Bharti S, Smith MA. Antimicrobial resistant Streptococcus pneumoniae: prevalence, mechanisms, and clinical Implications. Am J Ther. 2017 May; 24(3): 361-369.

(7) Silva-Costa C, Brito M, Aguiar S, Lopes JP, Ramirez M, Melo-Cristino J. et al. Dominance of vaccine serotypes in pediatric invasive pneumococcal infections in Portugal (2012–2015). Sci Rep – Nature. 2018 Jan; 8(1): 1-9.

(8) Tin Tin Htar M, Christopoulou D, Schmitt HJ. Pneumococcal serotype evolution in Western Europe. BMC Infect Dis. 2015 Sep; 15(1): 419-429.

(9) The European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters. Version 8.0, 2018. dostupno na sajtu: http://www.eucast.org/clinical_breakpoints/

(10) Vergison A, Tuerlinckx D, Verhaegen J, Malfroot A. Epidemiologic features of invasive pneumococcal disease in Belgian children: passive surveillance is not enough. Pediatrics. 2006 Oct; 118(3): 801-809.

(11) Müller Premru M, Beović B, Pokorn M, Cvitković Špik V. Serotypes and genotype of invasive pneumococci in the central part of Slovenia. Wien Klin Wochenschr. 2015 Sep; 127(1): 691-695.

(12) Guzvinec M, Tesović G, Tambić-Andrasević A, Zidovec-Lepej S, Vukić BT, Begovac J. The epidemiology of invasive Streptococcus pneumoniae disease in Croatian children. Med Sci Monit. 2008 Apr; 14(4): 59-64.

(13) Weinberger R, von Kries R, van der Linden M, Rieck T, Siedler A, Falkenhorst G. Invasive pneumococcal disease in children under 16 years of age: Incomplete rebound in incidence after the maximum effect of PCV13 in 2012/13 in Germany. Vaccine. 2018 Jan; 36(4): 572-577.

(14) The European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019. dostupno na sajtu: http://www.eucast.org/clinical_breakpoints/

(15) Kim L, McGee L, Tomczyk S, Beall B. Biological and epidemiological features of

antibiotic-resistant Streptococcus pneumoniae in pre- and post-conjugate vaccine

eras: a United States perspective. Clin Microbiol Rev. 2016 Apr; 29(3): 525-552.

(16) Hadnađev M, Gajić I, Mijač V, Kurucin T, Považan A, Opavski N. et al. Phenotypes and genotypes of macrolide-resistant Streptococcus pneumoniae in Serbia. Arch Biol Sci. 2014; 66(1): 99-105.

(17) Maraki S, Mantadakis E, Samonis G. Serotype distribution and antimicrobial resistance of adult Streptococcus pneumoniae clinical isolates over the period 2001-2008 in Crete, Greece. Chemotherapy. 2010 Aug; 56(4): 325-332.

(18) Torumkuney D, Nica M, Nistor I, Morrissey I. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Bulgaria, Romania, Serbia and Croatia. J Antimicrob Chemother 2018 Apr; 73(5): 2-13.

(19) Luminos M, Dorobat O, Jugulete G. Popescu GA. Nasopharyngeal carriage of Streptococcus pneumoniae in Romanian children before the introduction of the pneumococcal conjugated vaccination into the national immunization programme: a national, multi-centre, cross-sectional observational study. Int J Infect Dis. 2014 Oct; 29C(C): 169-173.

(20) Isturiz R, Sings H, Hilton B Reinert RR, Jodar L. Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert Rev Vaccines. 2017 Jul; 16(10): 1007-1027.